Obagi: Over-Hyped Aquisition Target Or Worthy Investment? Print E-mail
By Scott Matusow, Contributor   
Thursday, 05 July 2012 01:58
icon_closerlookThere has been abundant buzz on a company whose shares have been rising steadily since February. Obagi Medical Products (NASDAQ:OMPI) shaw shares hit $16.03 last week as speculators took positions during the latest round of buy-out chatter. 
Read more...
 
Dynavax Shares Holding Strong After Recent Run-Up Print E-mail
By Brian Wilson, Contributor   
Tuesday, 03 July 2012 05:43
icon_newsnotes Shares of Dynavax Technologies (DVAX), the clinical-stage pharmaceutical company focused primarily on hepatitis B, have been on the move. Their flagship project, HEPLISLAV, is an investigational hepatitis B vaccine. 
Read more...
 
After the big victory for Arena, what next? Print E-mail
By Brian Wilson, Contributor   
Monday, 02 July 2012 02:26
icon_bio-baggerArena Pharmaceuticals (NASDAQ:ARNA) made history last week, pushing through the first new diet drug in 13 years, with the Food and Drug Administration’s approval of Lorcaserin.
Read more...
 
Antares Focusing On Top Line Growth Print E-mail
By Scott Matusow, Contributor   
Friday, 29 June 2012 09:35
icon_stockresearchAntares Pharma (NASDAQ:ATRS) focuses on self-injection pharmaceutical products and technologies and topical gel -based products. The company's subcutaneous injection technology platforms include the Vibex MTX and Vibex QS disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.
Read more...
 
Vivus Shares Set To Benefit From Qnexa Despite Vulnerability Print E-mail
By Brian Wilson, Contributor   
Friday, 29 June 2012 07:26
icon_stockresearchVivus (NASDAQ:VVUS) is a company focused on obesity drugs. Its lead candidate, Qnexa, aims to curb obesity in patients with an extended release capsule containing 2 FDA-approved compounds (phentermine and topiramate).
Read more...
 
Highly Anticipated Catalyst Should Send Neptune Shares Even Higher Print E-mail
By M.E.Garza   
Thursday, 28 June 2012 00:46
icon_tradecatalystShares of Neptune Technologies & Bioressources (Nasdaq:NEPT) broke-out and closed +4.55% higher after trading 317% more shares than the daily average volume on Wednesday. This, after we alerted premium subscribers that a Preliminary Prospectus filing indicates that Neptune is finally preparing to announce a pending stock and warrant dividend for their 99% owned subsidiary NeuroBioPharm Inc. (“NeuroBioPharm”).
Read more...
 
<< Start < Prev 51 52 53 54 55 56 Next > End >>

Page 56 of 56

Newsletter